Valneva must immediately cease U.S. shipments and sales of Ixchiq, a vaccine for chikungunya virus. The FDA recently lifted a pause on dosing of Ixchiq, but the agency’s new safety alert is based on an assessment that found the vaccine appears to be causing chikungunya-like illness in recipients.
The French delegation at BIO on June 13-16 has a compelling story to tell about biopharma and medtech growth and investment in France and the U.S. Here's a preview of some of the companies that will be at the convention, events they will host and why you should check them out.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
French biotech Valneva has the green light to begin human trials for its investigational Lyme disease vaccine. There's a clear need, but the complex market has already rejected an effective vaccine, back in 2002.